In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line
✍ Scribed by Saskia J. A. M. Santegoets; Marco W. J. Schreurs; Allan J. Masterson; Ying Poi Liu; Steffen Goletz; Hans Baumeister; Esther W. M. Kueter; Sinéad M. Lougheed; Alfons J. M. van den Eertwegh; Rik J. Scheper; Erik Hooijberg; Tanja D. de Gruijl
- Publisher
- Springer-Verlag
- Year
- 2006
- Tongue
- English
- Weight
- 391 KB
- Volume
- 55
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract To identify tumor‐associated antigens as putative targets for developing immunotherapies against prostate cancer, we investigated the ability of T cells derived from the peripheral blood lymphocytes of prostate cancer patients to recognize autologous tumor cells. The technical challenge
The human melanocyte lineage-specific antigen gp100 contains several epitopes recognized by cytotoxic T lymphocytes (CTL). However, most of the epitopes reported to date are HLA-A2.1-restricted. Despite the high frequency of HLA-A2.1 in melanoma patients, effective population coverage requires the i
## Background and objectives: Using peripheral blood mononuclear cells (pbmcs) from a 10-year survivor with established human leukocyte antigen (hla)-a2(+) and mage-3(+) esophageal cancer cell line (kyse-170), we examined the induction of hla-a2-restricted and mage-3-gene-derived peptide (flwgpralv
To generate non-small cell lung cancer (NSCLC)-reactive lymphocytes, we transfected an HLA-A2-expressing human NSCLC line (1355) with the cDNA encoding the lymphocyte co-stimulatory molecule CD80. Following selection in G418, 1355.7 demonstrated stable cell-surface expression of CD80. Allogeneic mix